Severe Hypertriglyceridemia

CE / CME

Current Challenges and Emerging Treatments for the Management of Severe Hypertriglyceridemia

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: January 28, 2024

Expiration: January 29, 2025

Michael Miller
Michael Miller, MD, FACC, FAHA

Activity

Progress
1 2
Course Completed

Introduction

In this module, Michael Miller, MD, provides an overview of the current challenges and emerging treatments for the management of severe hypertriglyceridemia, including familial chylomicronemia syndrome (FCS). 

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity, and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many patients with severe hypertriglyceridemia do you treat in an average month?

Which of the following scenarios would most likely lead to severe hypertriglyceridemia?

Volanesorsen, a single-stranded antisense oligonucleotide that decreases the mRNA of APOC3, was not approved in the United States because of which adverse event?

Olezarsen, an investigational agent for the treatment of severe hypertriglyceridemia and FCS, works via which of the following mechanisms?

A 64-year-old patient with a past medical history of established cardiovascular disease is found to have persistent triglyceride elevations of 210 mg/dL.

Which of the following medications would be best to help reduce his risk of atherosclerotic cardiovascular disease (ASCVD)?